Redeye provides an initial take following the release of Optomed’s Q2 2025 report. Q2 sales fell short of our expectations, with the Devices segment contributing less than anticipated. We expect to make some downward revisions to our sales forecasts. Given the report, we anticipate a negative market reaction, with the share likely to decline by around 5–10% today.
LÄS MER
